Polyol ambitions: Sunar Misir invests in sorbitol and maltitol capacity

24 Sep 2018 --- Sunar Misir plans to reach an installed capacity of 100,000 tons for its sorbitol and maltitol facility in Adana (Turkey) by the end of 2019. Sunar Mısır has over 33 years of experience with corn-based ingredients and offers sustainably-sourced, Non-GMO starches and starch derivatives for the global market.

Lonza ups full year outlook as Capsugel integration starts to boost business

25 Jul 2018 --- Lonza has updated its outlook for the full year after reporting 8.2 percent organic (like-for-like) sales growth, double-digit organic CORE EBITDA and CORE EBIT growth during the first half of 2018. The company attributes growth to the successful integration of Capsugel and “buoyant demand” from pharmaceutical and biotech clients for products including viruses for gene therapy.

Bioavailability emerges as a key nutritional driver, says Frutarom Natural Solutions Chief

04 Jul 2018 --- The demand for natural, sustainable and integrated solutions, as well as growing calls for expressing bioavailability are all key drivers for today’s health and nutrition products, Frutarom’s President of Natural Solutions, Yoni Glickman has said. The business unit, which offers Flavor & Color, Food Protection and Health Benefits, accounts for about 25 percent of Frutarom’s turnover. An integrated cognitive health platform will be just one of the target areas for growth for the business, in the run-up to Frutarom’s US$7.1 billion acquisition by International Flavors & Fragrances (IFF), which was announced last May.

Lonza: Positive start to 2018, driven by expanding healthcare businesses

04 May 2018 --- Lonza has reported a “positive” start to 2018 led by the businesses along the healthcare continuum. The former Capsugel business, now part of Lonza Pharma & Biotech and Lonza Consumer Health, has shown a strong performance following good progress on business and functional integration, the company reports, without giving any details on financial figures. For the coming months, Lonza has announced plans to expand facilities in the US.

Fermentalg reports on Q1 revenue as US expansion begins

20 Apr 2018 --- Fermentalg, a French supplier of microalgae for nutrition and health, has reported first-quarter revenue of €232k whereas no income was recorded in Q1 2017. As of 31 March 2018, Fermentalg held gross cash and cash equivalents of €19.5 million compared to €21.8 million at 31 December 2017. Cash burn amounted to a €2.5 million outflow, stable compared to the previous quarter (excluding financing activities) and down €0.5 million from Q1 2017. Q1 was marked by progress achieved in bringing to market its DHA ORIGINS range of algal oils naturally rich in omega 3, as well as a US distribution agreement with Stauber, a leading North American supplier of specialty ingredients, the company reports.

GSK to take full ownership of Novartis stake in Consumer Healthcare Business for US$13bn

27 Mar 2018 --- GlaxoSmithKline (GSK) has reached an agreement with Novartis for the acquisition of Novartis’ 36.5 percent stake in its Consumer Healthcare Joint Venture for US$13 billion, just days after GSK exited the race to buy Pfizer's Consumer Healthcare Business. GSK reports that the Consumer Healthcare Business is well positioned to drive sales and earnings growth, powered by “category-leading Power Brands, science-based innovation and improved efficiencies.” Novartis reports that the sale will enable it to further focus on the development and growth of its core businesses.

Probi signs agreement with pharma company Cilag on probiotic OTC product

23 Mar 2018 --- Probi has signed a long-term agreement with Cilag, a member of the Johnson & Johnson Family of Companies, for the development of a probiotic product. The rapid growth of the probiotic segment and new exciting research on the importance of human microbiota have increased interest from pharma companies, and their consumer healthcare divisions, in probiotic product development, Probi notes.

Probi signs agreement with “global FMCG company” on gut health launch, enjoys Asia-Pacific growth

26 Jan 2018 --- Probi is seeking to further expand into the functional food space with a newly signed agreement with an as-of-yet unnamed global FMCG company. The partnership relates to the launch of a product containing Probi’s bacteria for gut health in North America. In its year-end report, Probi [which is majority owned by Symrise] notes that a launch in the North American market is planned for the second half of 2019, potentially followed by launches in other territories. The agreement is expected to have a significant impact on future sales and earnings in Probi’s Functional Food business area.

Fire-stricken BASF plant “back on stream” in March at the earliest

10 Jan 2018 --- BASF confirms that it still expects to start up the Citral plant in Ludwigshafen by March at the earliest following a blaze at the German site last fall. The latest progress reports including the potential availability of products are being detailed by the company which aims to keep customers and industry stakeholders informed of the progress of the repair work.

Nuritas raises €16m in Series A funding

21 Dec 2017 --- Nuritas has announced the close of a circa €16 million (US$19 million) Series A funding round led by Chicago-based Cultivian Sandbox Ventures. This brings the total invested to date to approximately €25 million, the company reports. The latest round of funding will support Nuritas’ global growth to address and solve many of the most pressing health issues of the day, including the diabetes epidemic.

Nutrition industry “feels positive” about new EU rules for novel foods: survey

19 Dec 2017 --- According to research by the organizers of Vitafoods Europe, many people working in the nutrition industry feel positive about the EU’s new process for the approval of novel foods. However, experts are warning that there could be adverse implications for some companies’ intellectual property portfolios. The new regulations on novel foods, defined as anything without a significant history of consumption in the EU before 15 May 1997, come into force on 1 January 2018. For the first time, the approval system will be centralized, with applications submitted to the European Commission rather than individual member states.

Seventure Partners’ microbiome portfolio nears critical milestones 

18 Dec 2017 --- Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector, is seeing rapid progress from innovation into human trials, with five of its portfolio companies advancing their human microbiome products with varying modalities and therapeutics targets in clinical trials.

Enzymotec and Frutarom merger gets shareholder green light

12 Dec 2017 --- The shareholders of Israeli specialty chemicals company Enzymotec Ltd. have approved by large majority the merger transaction between Frutarom and Enzymotec. The transaction was approved at Enzymotec’s General Meeting by 99.9 percent majority of shareholders present at the meeting and entitled to vote, Frutarom Industries Ltd. reports.

Cardiovascular risk in diabetes can be reduced using hormones, claims study

04 Dec 2017 --- Scientists at Joslin Diabetes Center in the US have taken another step toward solving a long-standing puzzle about heart health in Type 2 diabetes, with a finding that eventually may point towards more personalized patient care. Genetic analysis has linked the hormone known as glucagon-like peptide 1 (GLP-1) with cardiovascular mortality risks.

BASF plant fire: Force Majeure for vitamins and carotenoids at Citral plant

10 Nov 2017 --- BASF has announced that it has shut down its Citral plant in Ludwigshafen, Germany, and has had to declare Force Majeure for its Citral- and Isoprenol-based aroma ingredients following a fire on October 31 during the startup of the plant.

New MenaQ7 patents granted to NattoPharma in US, Israel and Australia

08 Nov 2017 --- NattoPharma ASA has successfully secured patents in Israel, the US and Australia for its “nature-identical synthesis” creating MenaQ7 PharmaPure Vitamin K2 as MK-7, adding further to the company’s patent portfolio.

BASF to enter US medical foods market with product to manage NAFLD

06 Nov 2017 --- BASF and DIEM Labs have entered into a distribution agreement to commercialize BASF’s first US medical food product for the dietary management of patients with non-alcoholic fatty liver disease (NAFLD). As part of this agreement, BASF has announced that it will use its scientific expertise and state-of-the-art manufacturing capabilities to provide a first-to-the-market medical food product to patients with NAFLD.

Oils and more: Neptune explores new frontiers in cannabis space

06 Nov 2017 --- Thanks to the complex regulatory situations surrounding the ingredient in various countries around the world, cannabis products currently do not have a clear roadmap for success. However, this doesn’t mean that there are not opportunities in the space. One company currently making a mark in the industry is Neptune Wellness Solutions.

Chr. Hansen: 10 percent organic growth for 2016/2017

25 Oct 2017 --- Chr. Hansen has announced its 2016/2017 Q4 results, with revenue reaching €283 million (US$333 million), compared to €256 million in Q4 2015/2016, corresponding to organic growth of 12 percent. Organic growth for the year as a whole reached 10 percent, and the EBIT margin before special items ended at 28.9 percent, up from 28.2 percent the year before.

Neptune chief eyes strong potential for new cannabis business as executive appointments installed

05 Oct 2017 --- Wellness products company Neptune Wellness Solutions has appointed Michel Timperio as President of its new Cannabis Business and Melody Harwood as Head of Scientific and Regulatory Affairs. Timperio will report to Jim Hamilton, President and CEO of Neptune.

loading